FENC Q3 2023 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M

Gross Profit

$6M94.9% margin

Operating Income

-$1M-15.6% margin

Net Income

-$2M-28.7% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+93.4%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$865,000

Balance Sheet

Total Assets

$19M

Total Liabilities

$30M

Stockholders' Equity

-$11M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$0	—
Gross Profit	$6M	-$60,404	+10337.7%
Operating Income	-$1M	-$8M	+86.5%
Net Income	-$2M	-$8M	+75.5%